NCT02613442

Brief Summary

Objective: To determine the clinical variables that influence aqueous outflow facility (Co) and intraocular pressure (IOP) in uveitis. Uveitic glaucoma is potentially blinding and occurs in 17-46% of chronic uveitis patients. Uveitic activity causes fluctuating IOP due to decreased Co, increased uveoscleral outflow or decreased aqueous production. Specific Aim 1: To evaluate the risk factors for high IOP and low Co in uveitis Hypothesis: Decreased Co and increased IOP will occur with increasing anterior chamber (AC) flare, AC cells, degree of synechial angle closure, increased duration of disease, higher uveitis activity and increasing steroid use Specific Aim 2: To determine prospectively the effect of AC flare on Co and IOP in "quiescent" uveitis Hypothesis: AC flare even in the absence of AC cells will cause progressive decline in Co. Methods: In this proof of concept study, thirty consecutive patients with acute or chronic uveitis will be recruited from the uveitis clinic. Ten patients with "quiescent" uveitis (no AC cells) will be recruited for the prospective arm and followed every 2-3 months for 3 visits. Co will be measured using 2-minute pneumatonometer tonography. The effect of risk factors on IOP and Co in uveitis will be studied using generalized linear modelling techniques. These risk factors include AC flare (using the laser flare meter), AC cells, degree of angle closure (by gonioscopy), duration of disease, disease activity and corticosteroid use within the last year. In the prospective study, the patients will be divided into subgroups with low flare (\< 20ph/ms) and high flare (≥ 20 ph/msec) and the change in Co and IOP will be analyzed. Impact: This will be the first study to systematically analyze the risk factors for decrease in Co and increase in IOP in uveitis and to prospectively evaluate the effect of AC flare on Co. Proof that AC flare can damage the trabecular meshwork will corroborate previous experimental evidence and change the paradigm of uveitis treatment. Knowledge of the risk factors that affect Co and IOP will aid in identifying patients that may need escalation of their uveitis or glaucoma treatment to prevent optic nerve damage.

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Apr 2017

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 12, 2015

Completed
12 days until next milestone

First Posted

Study publicly available on registry

November 24, 2015

Completed
1.4 years until next milestone

Study Start

First participant enrolled

April 13, 2017

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 13, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 13, 2017

Completed
Last Updated

September 3, 2024

Status Verified

August 1, 2024

Enrollment Period

Same day

First QC Date

November 12, 2015

Last Update Submit

August 29, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • change in Aqeuous outflow facility

    tonographic outflow facility calculations using pneumatonography

    9 months

Secondary Outcomes (1)

  • change in intraocular pressure measured by pneumatonometer

    9 months during the study and previous 1 year historical eye pressure

Eligibility Criteria

Age19 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Prospective subjects will be identified from the patient population pool in the Uveitis Clinic at the Truhlsen Eye Institute, University of Nebraska Medical Center, Department of Ophthalmology and Visual Sciences.

You may qualify if:

  • Subjects must be 18 years or older
  • Subjects have a diagnosis of uveitis
  • Ability to cooperate for tonography

You may not qualify if:

  • Any current corneal abrasion
  • Hypersensitivity to proparacaine
  • history of vitrectomy
  • hypotony (Intraocular pressure \< 5 mm Hg)
  • aphakia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

UveitisGlaucoma

Condition Hierarchy (Ancestors)

Uveal DiseasesEye DiseasesOcular Hypertension

Study Officials

  • Deepta Ghate, MD

    University of Nebraska

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 12, 2015

First Posted

November 24, 2015

Study Start

April 13, 2017

Primary Completion

April 13, 2017

Study Completion

April 13, 2017

Last Updated

September 3, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share